Key Takeaways
Nexalin Technology (Nasdaq: NXL) will advance its HALO Clarity device into a 160-participant pivotal clinical trial starting in the second quarter of 2026, a critical step in its strategy to secure U.S. Food and Drug Administration clearance for the novel insomnia treatment.
"We believe the Nexalin HALO Clarity medical device represents a unique and advanced approach to non-invasive drug-free treatment for patients with moderate-to-severe insomnia," said Mark White, Chief Executive Officer of Nexalin Technology.
The randomized, triple-blinded, sham-controlled study is designed to support a De Novo Classification Request with the FDA. This regulatory path is for new device types and could distinguish Nexalin’s Deep Intracranial Frequency Stimulation (DIFS™) technology from existing neurostimulators. The global sleep tech device market was estimated at $29.3 billion in 2025, according to Precedence Research.
A successful trial and subsequent De Novo clearance would establish a new product category, opening a large and underserved market for a non-pharmacologic insomnia treatment. For investors, this represents a significant potential catalyst for Nexalin, though failure would pose a major setback to its clinical and commercial ambitions.
Nexalin is collaborating with Lindus Health, an Accountable Research Organization, to manage the trial from protocol finalization through data analysis and submission. The study’s primary goal is to provide the clinical evidence needed for the FDA to grant a De Novo request, which, if successful, would create a new class of medical device and differentiate the HALO Clarity from current stimulation technologies.
The company’s strategy builds on previously published clinical data that showed statistically significant improvements in treatment parameters compared to a sham device. Nexalin’s non-invasive neurostimulation platform is also being investigated for use in treating depression, TBI, PTSD, and Alzheimer’s disease.
Maxim Group analyst Anthony Vendetti recently reiterated a Buy rating on Nexalin Technology with a price target of $2.00. The company's shares closed at $0.37 prior to the announcement. For the quarter ending December 31, Nexalin reported revenue of $171.9 thousand and a GAAP net loss of $2.38 million, compared to revenue of $27.18 thousand and a net loss of $2.83 million in the year-ago period.
This article is for informational purposes only and does not constitute investment advice.
